Study on Initial Dosage Setting of Vancomycin Injection.

Maeda, Yorinobu; Konishi, Toshio; Saionji, Shinji; Funakoshi, Sachiyo; Nakamura, Mamoru; Nii, Wakako; Masaki, Fumiko; Tsukiai, Satsuki

doi:10.5649/jjphcs1975.25.517

Cited by 8 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They reported that Maeda's method achieved the therapeutic range more frequently than the other 3 methods, and that the Bayesian focusing technique was valuable in correcting the vancomycin dosage regimen more precisely. 22) Collectively, our previous report, 12) the present report, and the reports by Teramachi et al 21) and Nagano et al 23) demonstrate the clinical usefulness of Maeda's method in setting the initial dosage regimen in vancomycin therapy for adult MRSA patients.…”

Section: Discussionsupporting

confidence: 77%

“…Previously, we analyzed retrospectively vancomycin TDM data obtained using a standard dosage regimen in 99 adult Japanese MRSA patients. 12) Of those patients, 65 received vancomycin at a dose of more than 1,000 mg (at 12 h, 24 h or 48 h intervals) and 35 patients (54z) reached the desired target vancomycin range after several administrations. In contrast, only 2 patients out of 34 (5.9z) reached the target vancomycin range when they received a dose of less than 750 mg (750 mg, 2 patients and 500 mg, 32 patients).…”

Section: Discussionmentioning

confidence: 99%

“…Previously, we examined Maeda's nomogram in 6 adult MRSA patients and found that 4 patients (67z) achieved the therapeutic range of vancomycin in the early stage of therapy. 12 In the present study, we re-evaluated the clinical e‹cacy of Maeda's nomogram regimen by increasing patient numbers and by comparing TDM data and clinical therapeutic responses with those obtained using a currently available standard dosage regimen. With Maeda's nomogram method, 4 diŠerent dosage modalities were required for 53 MRSA patients depending on their renal function (ratio of modalities W patients number＝0.075) ( Table 1).…”

Section: Discussionmentioning

confidence: 99%

“…Maeda's nomogram 12) sets the dosing interval (days) in relation to individual CLcr (mL W min), with vancomycin doseˆxed at 1,000 mg and CLcr estimated using the nomogram (Fig. 1).…”

Section: Methodsmentioning

confidence: 99%

“…Maeda's nomogram xes the vancomycin dose at 1,000 mg and varies the dosing interval based on individual CLcr values. 12) The present clinical trials were carried out to evaluate the clinical e‹cacy of Maeda's nomogram by comparing the therapeutic drug monitoring (TDM) data and clinical responses obtained with those obtained using a standard dosage regimen in adult Japanese MRSA pneumonia patients.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Evaluation of Clinical Efficacy of Maeda’s Nomogram for Vancomycin Dosage Adjustment in Adult Japanese MRSA Pneumonia Patients

Maeda

Omoda

Fukuhara

et al. 2006

Drug Metabolism and Pharmacokinetics

Self Cite

View full text Add to dashboard Cite

The clinical efficacy of Maeda's nomogram for vancomycin dosage adjustment was evaluated by comparison with a standard dosage regimen (package insert information: vancomycin dose reduced in elderly patients and patients with renal dysfunction, with Moellering's nomogram used for renal-dysfunction patients) in adult Japanese MRSA pneumonia patients. Using Maeda's nomogram, the vancomycin dose is fixed at 1,000 mg while the dosing interval is varied in accordance with individual creatinine clearance. Using a standard dosage regimen, 5 patients out of 27 (18.5%) achieved target plasma levels of vancomycin (25-40 microg/mL for peak and 5-15 microg/mL for trough) within 2-6 days. Using Maeda's nomogram, 38 patients out of 53 (71.7%) achieved target levels in that time. A higher clinical response (complete resolution of all signs and symptoms of MRSA infection) to vancomycin therapy was also obtained with Maeda's nomogram when evaluated approximately 2-weeks after discontinuation of vancomycin therapy (43.4% versus 18.5% for the standard regimen). In conclusion, the Maeda's nomogram regimen with a 1,000 mg vancomycin dose was shown to achieve target plasma levels of vancomycin at a higher rate and provide higher clinical efficacy in vancomycin therapy of MRSA pneumonia patients, as compared with the currently available standard dosage regimen.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Maeda's nomogram 12) sets the dosing interval (days) in relation to individual CLcr (mL W min), with vancomycin doseˆxed at 1,000 mg and CLcr estimated using the nomogram (Fig. 1).…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations